Alligator Bioscience to present new pre-clinical data for ADC-1013 and ATOR-1015 at PEGS conference in Boston, May 4

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will present new pre-clinical data on the CD40 agonistic immuno-oncology antibody ADC-1013, and on the bispecific OX40 and CTLA-4 dual targeting antibody ATOR-1015, at the PEGS Third Annual Agonist Immunotherapy Targets conference in Boston.  
Dr Peter Ellmark, Principal Scientist at Alligator, will give an oral presentation with the title “Tumor-Directed Immunotherapy – Tumor-Localized Immune Activation Using TNFR-SF Agonistic Antibodies” in the evening on May 4 Swedish time.

Alligator’s lead programme, ADC-1013, which has a pre-clinical profile indicating good safety and applicability in multiple tumor types, is currently being investigated in a second Phase I dose escalation trial. The immuno-oncology antibody was out-licensed in August 2015 to Janssen Biotech Inc., an oncology company within the Johnson & Johnson group.

Alligator’s wholly-owned product ATOR-1015 is a bispecific immuno-oncology compound that has the potential to be a first in class dual immune activating antibody.

“We are excited to be presenting these early data which provide further validation of the strength of our pipeline of tumor-directed immuno-oncology antibodies”, says Per Norlén, Chief Executive Officer of Alligator Bioscience. “Alligator is deeply rooted in immuno-oncology and, as one of the first entrants into the scientific area in 2008, has successfully built a pipeline with the potential to provide much-needed treatments to patients suffering from multiple metastasizing cancers.”

For further information, please contact:

Per Norlén, CEO
Telephone: + 46 46 286 42 80 (switchboard)

Rein Piir, VP Investor Relations at Alligator
Telephone: +46 708 537292

Per-Olof Schrewelius, CFO
Telephone: +46 46 286 42 85

The information in the press release was submitted for publication at 1 p.m. CET on 28 April, 2017.

About Alligator
Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit

About ADC-1013
ADC-1013 is a human, monospecific, agonistic, IgG1 antibody intended for immunotherapy of cancer. In August 2015, Alligator entered a collaboration with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which has the global development rights to ADC-1013. The drug candidate targets the co-stimulatory receptor CD40, which is expressed on, for example, antigen-presenting dendritic cells. The dendritic cells reside in blood vessels and various tissues where they discover and digest proteins from viruses, bacteria or cancer cells. Next, the digested proteins are presented to so-called T-cells which are activated and kill the infected cells or the cancer cells. ADC-1013 activates CD40 on dendritic cells, enabling them to activate T-cells more effectively and thereby increasing the immune system's attack of the cancer.

About ATOR-1015
ATOR-1015 is a bispecific antibody for tumor-directed immunotherapy and is fully owned and developed by Alligator for the treatment of metastatic cancer. ATOR-1015 binds to two different immune receptors: the checkpoint receptor CTLA-4, and the co-stimulatory receptor OX40. ATOR-1015 is developed to reduce immune suppressive functions including regulatory T cells, as well as to induce direct T-cell activation. The immune activation is augmented in areas where both target molecules are expressed at high levels, notably in the tumor microenvironment, which is believed to reduce adverse immune reactions.

Updated 2017-04-28